AstraZeneca got a complete response letter (or CRL) for their hyperkalemia drug ZS-9 which would be have been competing with Relypsa's newly-approved Veltassa.
It may take up to 2 years by some estimates to address the issues raised in the CRL (less time if they are lucky). In the meantime, they having nothing to sell in the hyperkalemia market after spending billions to buy ZS pharma.
You should really learn the difference between "could care less" and "couldn't care less".
Each data point on an exponential growth curve is a percentage. Exponential growth just refers to the implied growth rate of the entire series of data points.
Exponential growth can be very small or very large, or even negative. 1% growth per month is exponential , just as 100% growth per month is, just as losing 25% a month is--it is just a different exponent.
Consequently, without a reference to the "expected growth" (which is what the prior poster asked), saying something like "we were hoping for exponential growth" is meaningless, and just demonstrates that you don't know what "exponential growth" means.
As it happens, the new patient numbers were up 13.90%, this month, while they had been down the prior month. That is certainly better that it had been doing; (However, it cannot be described as an "exponential" change, since the prior month was down, negative exponential "growth" would require a successive loss, which would be bad. Exponential changes are not always good.)
In addition, the outpatient numbers were up 32.54%, and had been up 31.44% the prior month. Those are not as good as the increases in the earlier months, but if those numbers hold, that would be an exponential increase of just over 30% a month. That would be a good exponential increase, but it is also possible that the rate of increase could grow as well with the removal of the threat of competition, at least for now.
"for some unclear reason oil and solar move in together"?
Solar is less attractive on a relative cost benefit basis when oil is cheap, and more attractive on a relative cost benefit basis when oil is expensive, that's just basic supply and demand pricing.
I don't see how that could be construed as "unclear".
I've watched SGEN, particularly since my sister died from relapsed Hodgkin's lymphoma only a short time before ADCETRIS was approved. Had it been around, it might have saved her, though we will never know.
Having that personal connection made me hesitate to get in too deep on SGEN, (though I did hold it at one time, I have no holdings now), since my desire to have them succeed could cloud my judgement.
What makes you think that it is going to be huge in the upcoming year?
If you read the above, the key portion is the following:
"A ferric citrate formulation for treating hyperphosphatemia is a new therapeutic that not only suppresses the accumulation of phosphorus in patients with chronic kidney disease-mineral bone disorders (CKD-MBD), but also ameliorates anemia caused by iron deficiency. In contrast, it has been demonstrated that intravenous iron injection markedly increases oxidative stress."
and "Interestingly, oxidative stress markers [using Ferric Citrate] did not increase significantly, and anti-oxidative capacity was not significantly decreased at 6 months after the drug administration. Similarly, no change was observed in any inflammation markers. The ferric citrate formulation induces negligible oxidative stress in CKD-MBD patients receiving dialysis under the present clinical condition."
This means that Ferric Citrate has favorable qualities for treating iron-deficiency anemia (IDA) relative to intravenous iron injection. Coupled with the recent study on IDA that showed its effectiverness, this is good news.
Given that both of you claim to be baffled as to the price action, what good are the technicals doing you?
Trading on technicals successfully requires knowing when they apply and when they don't.
Technicals work well in the absence of fundamental news, but significant fundamental news (especially when not fully understood, as evidenced by the price action) trump technicals more often than not. Once the fundamental news is absorbed and properly understood then technicals become meaningful again.
It has nothing to do with "gaps" or "support".
Read the threads entitled "Klarman's ownership position" and "Script numbers?"
Read the Motley Fool article on the Yahoo Summary page for KERX, which gives a much better explanation for the changes on the new 13D.
The article is titled "Why Keryx Biopharmaceuticals Shouldn't Be Up Today".
I'd like your interpretation to be true, but I have to be realistic.
Look to see it move tomorrow. They are marketing recently approved Veltassa for hyperkalemia. Astrazeneca had a competing product up for an NDA and received a CRL, which is good news for RLYP. RLYP was up AH, and should move even higher with potential for a buyout.
The hyperkalemia space is similar in some respects to the hyperphosphatemia space that KERX competes in. Both companies are candidates for buyouts in their respective markets.
straZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for treatment of hyperkalaemia
PUBLISHED 27 May 2016
27 May 2016
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca.
The CRL refers to observations arising from a pre-approval manufacturing inspection. The FDA also acknowledged receipt of recently-submitted data which it has yet to review. The CRL does not require the generation of new clinical data. AstraZeneca and ZS Pharma are evaluating the content of the CRL and will work closely with the FDA to determine the appropriate next steps for the NDA.
AstraZeneca remains committed to the development of sodium zirconium cyclosilicate as a treatment option for patients with hyperkalaemia. Interactions are ongoing with other health authorities in the European Union and Australia, where sodium zirconium cyclosilicate is currently under separate regulatory review.
I am on the FDA email list, and got an email about it at 3PM Eastern time.